recombinant vesicular stomatitis virus vector-based HIV-1 vaccine (Profectus BioSciences)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namerecombinant vesicular stomatitis virus vector-based HIV-1 vaccine (Profectus BioSciences)

Drug Alias NamerVSV vector-based HIV-1 vaccine (Profectus BioSciences)rVSVIN HIV-1 gag vaccine (Profectus Biosciences)recombinant VSV vector-based HIV-1 vaccine (Profectus BioSciences)

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine

Mechanisms of ActionImmunomodulatorsGlycosaminoglycan modulators

TargetsGlycosaminoglycan

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesWyeth Pharmaceuticals Co

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesWyeth Pharmaceuticals Co +[2]

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A